LAUSR

Hemophilia A is a rare X-chromosome linked congenital bleeding disorder caused by a deficiency of coagulation factor VIII. People with severe hemophilia have clotting factor levels <1% and often experience spontaneous bleeding, mainly into large joints and muscles. The primary aim of care is to prevent and treat bleeding episodes with the deficient clotting factor or non-factor therapies such as emicizumab, a monoclonal antibody that mimics factor VIII function [1–3]. In a healthy population, extracorporeal shock wave therapy (ESWT) is considered one of the most effective approaches in treating plantar fasciitis, providing substantial relief to approximately 80% of patients and showing no serious adverse events [4–7]. Possible adverse events are hematomas, pain, redness of the skin/blistering and tendon edema [8]. The guidelines of the German-speaking International Association for Extracorporeal Shock Wave Therapy (DIGEST) as well as the International Society for Medical Shockwave Treatment (ISMST) state that high-energy (not lowenergy) ESWT is associated with the risk of bleeding and is therefore contraindicated in patients with coagulopathy [8]. A systematic review evaluated the